IP Library Granted Patent US 10,597,659
Granted Patent B2
US 10,597,659 · App. 16/040,795 · Granted Mar 24, 2020

Multi-conjugate of SiRNA and preparing method thereof

Inventors: Tae Gwan Park (Daejeon, KR); Hye Jung Mok (Daejeon, KR); Soo Hyeon Lee (Daejeon, KR)
Assignee: KAIST IP CO., LTD.
C12N15/1136C12N15/111C12N15/113C12N2310/14C12N2310/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,659
App. No.
16/040,795
Granted
Mar 24, 2020
Kind
B2
Abstract

The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency.

Claims (30)

1. A purified single-stranded homodimeric RNA having the structure

wherein each is a subunit of RNA;

wherein each of the subunits is identical;

wherein and • and ∘ are distinct functional groups mediating a bond between the subunits; and

wherein the bond is mediated by a bivalent cross-linking agent comprising maleimide, NHS (N-hydroxysuccinimide), vinylsulfone, iodoacetyl, nitrophenyl azide, isocyanate, pyridyldisulfide, hydrazide, or hydroxyphenyl azide.

2. The purified single-stranded homodimeric RNA of claim 1 , wherein the cross-linking agent has a molecular weight in the range of 100 Daltons to 10,000 Daltons.

3. The purified single-stranded homodimeric RNA of claim 1 , wherein the cross-linking agent comprises DTME (dithiobismaleimidoethane), sulfo-SMCC (sulfosuccinimidyl-4 [N-maleimidomethyl]cyclohexane-1-carboxylate), or BM(PEG) 2 (1,8-bis(maleimido)diethyleneglycol).

4. The purified single-stranded homodimeric RNA of claim 1 , wherein the subunits are bonded 3′ end to 3′ end, or 5′ end to 5′ end.

5. The purified single-stranded homodimeric RNA of claim 1 , wherein the subunits are bonded 3′ end to 5′ end.

6. The purified single-stranded homodimeric RNA of claim 1 , wherein subunits are sense or antisense siRNAs.

7. The purified single-stranded homodimeric RNA of claim 1 , wherein the subunits are complementary to c-myc, c-myb, c-fos, c-jun, bcl-2, VEGF, VEGF-B, VEGF-C, VEGF-D, or PIGF mRNA.

8. The purified single-stranded homodimeric RNA of claim 1 , wherein each of the subunits has 15-50 nucleotides or 15-29 nucleotides.

9. A purified single-stranded homodimeric RNA having the structure

wherein each is a subunit of RNA;

wherein each of the subunits is identical;

wherein and • and ∘ are distinct functional groups mediating a bond between the subunits; and

wherein the bond is a reductant cleavable bond, a bio-cleavable bond, or an enzyme cleavable bond.

10. The purified single-stranded homodimeric RNA of claim 9 , wherein the subunits are bonded 3′ end to 3′ end.

11. The purified single-stranded homodimeric RNA of claim 9 , wherein the subunits are bonded 5′ end to 5′ end.

12. The purified single-stranded homodimeric RNA of claim 9 , wherein the subunits are bonded 3′ end to 5′ end.

13. The purified single-stranded homodimeric RNA of claim 9 , wherein subunits are sense or antisense siRNAs.

14. The purified single-stranded homodimeric RNA of claim 9 , wherein the subunits are complementary to c-myc, c-myb, c-fos, c-jun, bcl-2, VEGF, VEGF-B, VEGF-C, VEGF-D, or PIGF mRNA.

15. The purified single-stranded homodimeric RNA of claim 9 , wherein each of the subunits has 15-50 nucleotides or 15-29 nucleotides.

16. The purified single-stranded homodimeric RNA of claim 9 , wherein the bond is a reductant cleavable bond.

17. The purified single-stranded homodimeric RNA of claim 16 , wherein reductant cleavable bond is disulfide.

18. The purified single-stranded homodimeric RNA of claim 17 , wherein the subunits are bonded 3′ end to 3′ end, or 5′ end to 5′ end.

19. A method of synthesizing a purified single-stranded homodimeric RNA according to claim 1 , the method comprising covalently bonding

to a bivalent cross-linking agent comprising maleimide, NHS (N-hydroxysuccinimide), vinylsulfone, iodoacetyl, nitrophenyl azide, isocyanate, pyridyldisulfide, hydrazide, or hydroxyphenyl azide, thereby synthesizing a single-stranded homodimeric RNA.

20. A method of synthesizing a purified single-stranded homodimeric RNA according to claim 9 , the method comprising covalently bonding

thereby synthesizing the purified single stranded homodimeric RNA, wherein the bond is a reductant cleavable bond, bio-cleavable bond, or enzyme cleavable bond.

Assignments (3)
CHANGE OF NAME Recorded Nov 16, 2020
From: KAIST-IP CO., LTD
To: KIP CO., LTD.
Reel/Frame 054432/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: PARK, TAE GWAN; MOK, HYE JUNG; LEE, SOO HYEON
To: KAIST IP CO., LTD.
Reel/Frame 051604/0138 →
LICENSE Recorded Mar 13, 2019
From: KIP CO. LTD.
To: MPEG LA, LLC
Reel/Frame 048583/0109 →
Priority Claims (1)
KR 10-2009-0021705 · Mar 13, 2009 · national
Continuity (5)
Continuation 15483528 · Apr 10, 2017
Continuation 14312530 · Jun 23, 2014
Continuation 14048951 · Oct 8, 2013
Continuation 12514306
Related Publication 20190185861A1 · Jun 20, 2019
Cited By (2)
US 12,378,551 US 12,618,071